2025

Mayne, K. J. et al. (2025) Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation, 40(4), pp. 720-730. (doi: 10.1093/ndt/gfae203) (PMID:39277784) (PMCID:PMC7616479)

The EMPA-KIDNEY Collaborative Group, and , (2025) Long-term effects of empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 392(8), pp. 777-787. (doi: 10.1056/NEJMoa2409183) (PMID:39453837) (PMCID:PMC7616743)

2024

Judge, P. K. et al. (2024) The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfae263) (PMID:39533115) (Early Online Publication)

Mayne, K. J., Hanlon, P. and Lees, J. S. (2024) Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines. Diabetes, Obesity and Metabolism, 26(S6), pp. 43-54. (doi: 10.1111/dom.15625) (PMID:38699995)

Pinter, J., Canaud, B., Mayne, K. J., Stuard, S., Moissl, U., Kooman, J., Jager, K. J., Chesnaye, N. C., Smyth, B. and Genser, B. (2024) Associations of abnormal fluid status, plasma sodium disorders, and low dialysate sodium with mortality in hemodialysis patients. Clinical Journal of the American Society of Nephrology, 19(11), pp. 1444-1452. (doi: 10.2215/cjn.0000000000000552) (PMID:39292852)

Fletcher, R. A. et al. (2024) Effects of Sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD: a meta-analysis of CKD progression trials. Clinical Journal of the American Society of Nephrology, 19(9), pp. 1180-1182. (doi: 10.2215/CJN.0000000000000470) (PMID:38622766)

Mayne, K. J. et al. (2024) Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial. Clinical Journal of the American Society of Nephrology, 19(9), pp. 1119-1129. (doi: 10.2215/cjn.0000000000000498) (PMID:38949880)

Nangaku, M. et al. (2024) Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY. Clinical and Experimental Nephrology, 28(6), pp. 588-595. (doi: 10.1007/s10157-024-02489-4) (PMID:38643286) (PMCID:PMC11116192)

Morrow, A. J. et al. (2024) Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization. Communications Medicine, 4, 32. (doi: 10.1038/s43856-024-00455-5) (PMID:38418616) (PMCID:PMC10901805)

EMPA-KIDNEY Collaborative Group, and , (2024) Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes and Endocrinology, 12(1), pp. 39-50. (doi: 10.1016/S2213-8587(23)00321-2) (PMID:38061371) (PMCID:PMC7615591)

Judge, P. et al. (2024) Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes and Endocrinology, 12(1), pp. 51-60. (doi: 10.1016/S2213-8587(23)00322-4) (PMID:38061372)

2023

Mayne, K. J. et al. (2023) Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease. Journal of the American Society of Nephrology, (doi: 10.1681/ASN.0000000000000271) (PMID:38082486) (Early Online Publication)

Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)

Mayne, K. J., Sullivan, M. K. and Lees, J. S. (2023) Sex and gender differences in the management of chronic kidney disease and hypertension. Journal of Human Hypertension, (doi: 10.1038/s41371-023-00843-9) (Early Online Publication)

Mayne, K. J., Lees, J. S. and Mark, P. B. (2023) Cardiovascular complications of chronic kidney disease. Medicine, 51(3), pp. 190-195. (doi: 10.1016/j.mpmed.2022.12.008)

Mayne, K. J., Lees, J. S. , Rutherford, E., Thomson, P. C., Traynor, J. P., Dey, V. , Lang, N. N. and Mark, P. B. (2023) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort. Clinical Kidney Journal, 16(3), pp. 512-520. (doi: 10.1093/ckj/sfac248) (PMID:36865003) (PMCID:PMC9972818)

Mayne, K. J., Lees, J. S. and Herrington, W. G. (2023) Bioimpedance in CKD: an untapped resource? Nephrology Dialysis Transplantation, 38(3), pp. 583-585. (doi: 10.1093/ndt/gfac275) (PMID:36260361) (PMCID:PMC9976732)

The EMPA-KIDNEY Collaborative Group, and , (2023) Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), pp. 117-127. (doi: 10.1056/nejmoa2204233) (PMID:36331190) (PMCID:PMC7614055)

Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)

2022

Baigent, C. et al. (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, 400(10365), pp. 1788-1801. (doi: 10.1016/S0140-6736(22)02074-8) (PMID:36351458) (PMCID:PMC7613836)

Mayne, K. J., Shemilt, R., Keane, D. F., Lees, J. S. , Mark, P. B. and Herrington, W. G. (2022) Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review. Journal of Cardiac Failure, 28(11), pp. 1628-1641. (doi: 10.1016/j.cardfail.2022.08.005) (PMID:36038013)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Rankin, A. J. , Mayne, K., Allwood-Spiers, S., Hall Barrientos, P., Roditi, G., Gillis, K. A. and Mark, P. B. (2022) Will advances in functional renal magnetic resonance imaging translate to the nephrology clinic? Nephrology, 27(3), pp. 223-230. (doi: 10.1111/nep.13985) (PMID:34724286)

2021

Berry, C. et al. (2021) Post-COVID-19 illness trajectory: a multisystem investigation [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1053331/v1)

Articles

Mayne, K. J. et al. (2025) Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation, 40(4), pp. 720-730. (doi: 10.1093/ndt/gfae203) (PMID:39277784) (PMCID:PMC7616479)

The EMPA-KIDNEY Collaborative Group, and , (2025) Long-term effects of empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 392(8), pp. 777-787. (doi: 10.1056/NEJMoa2409183) (PMID:39453837) (PMCID:PMC7616743)

Judge, P. K. et al. (2024) The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfae263) (PMID:39533115) (Early Online Publication)

Mayne, K. J., Hanlon, P. and Lees, J. S. (2024) Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines. Diabetes, Obesity and Metabolism, 26(S6), pp. 43-54. (doi: 10.1111/dom.15625) (PMID:38699995)

Pinter, J., Canaud, B., Mayne, K. J., Stuard, S., Moissl, U., Kooman, J., Jager, K. J., Chesnaye, N. C., Smyth, B. and Genser, B. (2024) Associations of abnormal fluid status, plasma sodium disorders, and low dialysate sodium with mortality in hemodialysis patients. Clinical Journal of the American Society of Nephrology, 19(11), pp. 1444-1452. (doi: 10.2215/cjn.0000000000000552) (PMID:39292852)

Fletcher, R. A. et al. (2024) Effects of Sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD: a meta-analysis of CKD progression trials. Clinical Journal of the American Society of Nephrology, 19(9), pp. 1180-1182. (doi: 10.2215/CJN.0000000000000470) (PMID:38622766)

Mayne, K. J. et al. (2024) Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial. Clinical Journal of the American Society of Nephrology, 19(9), pp. 1119-1129. (doi: 10.2215/cjn.0000000000000498) (PMID:38949880)

Nangaku, M. et al. (2024) Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY. Clinical and Experimental Nephrology, 28(6), pp. 588-595. (doi: 10.1007/s10157-024-02489-4) (PMID:38643286) (PMCID:PMC11116192)

Morrow, A. J. et al. (2024) Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization. Communications Medicine, 4, 32. (doi: 10.1038/s43856-024-00455-5) (PMID:38418616) (PMCID:PMC10901805)

EMPA-KIDNEY Collaborative Group, and , (2024) Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes and Endocrinology, 12(1), pp. 39-50. (doi: 10.1016/S2213-8587(23)00321-2) (PMID:38061371) (PMCID:PMC7615591)

Judge, P. et al. (2024) Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes and Endocrinology, 12(1), pp. 51-60. (doi: 10.1016/S2213-8587(23)00322-4) (PMID:38061372)

Mayne, K. J. et al. (2023) Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease. Journal of the American Society of Nephrology, (doi: 10.1681/ASN.0000000000000271) (PMID:38082486) (Early Online Publication)

Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)

Mayne, K. J., Sullivan, M. K. and Lees, J. S. (2023) Sex and gender differences in the management of chronic kidney disease and hypertension. Journal of Human Hypertension, (doi: 10.1038/s41371-023-00843-9) (Early Online Publication)

Mayne, K. J., Lees, J. S. and Mark, P. B. (2023) Cardiovascular complications of chronic kidney disease. Medicine, 51(3), pp. 190-195. (doi: 10.1016/j.mpmed.2022.12.008)

Mayne, K. J., Lees, J. S. , Rutherford, E., Thomson, P. C., Traynor, J. P., Dey, V. , Lang, N. N. and Mark, P. B. (2023) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort. Clinical Kidney Journal, 16(3), pp. 512-520. (doi: 10.1093/ckj/sfac248) (PMID:36865003) (PMCID:PMC9972818)

Mayne, K. J., Lees, J. S. and Herrington, W. G. (2023) Bioimpedance in CKD: an untapped resource? Nephrology Dialysis Transplantation, 38(3), pp. 583-585. (doi: 10.1093/ndt/gfac275) (PMID:36260361) (PMCID:PMC9976732)

The EMPA-KIDNEY Collaborative Group, and , (2023) Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), pp. 117-127. (doi: 10.1056/nejmoa2204233) (PMID:36331190) (PMCID:PMC7614055)

Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)

Baigent, C. et al. (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, 400(10365), pp. 1788-1801. (doi: 10.1016/S0140-6736(22)02074-8) (PMID:36351458) (PMCID:PMC7613836)

Mayne, K. J., Shemilt, R., Keane, D. F., Lees, J. S. , Mark, P. B. and Herrington, W. G. (2022) Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review. Journal of Cardiac Failure, 28(11), pp. 1628-1641. (doi: 10.1016/j.cardfail.2022.08.005) (PMID:36038013)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Rankin, A. J. , Mayne, K., Allwood-Spiers, S., Hall Barrientos, P., Roditi, G., Gillis, K. A. and Mark, P. B. (2022) Will advances in functional renal magnetic resonance imaging translate to the nephrology clinic? Nephrology, 27(3), pp. 223-230. (doi: 10.1111/nep.13985) (PMID:34724286)

Berry, C. et al. (2021) Post-COVID-19 illness trajectory: a multisystem investigation [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1053331/v1)